180 related articles for article (PubMed ID: 32556456)
1. Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
Lucijanic M; Jaksic O
Ann Hematol; 2020 Sep; 99(9):2191-2192. PubMed ID: 32556456
[No Abstract] [Full Text] [Related]
2. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
[TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
[TBL] [Abstract][Full Text] [Related]
4. Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine.
Zimmer P; Mierau A; Bloch W; Strüder HK; Hülsdünker T; Schenk A; Fiebig L; Baumann FT; Hahn M; Reinart N; Hallek M; Elter T
Leuk Lymphoma; 2015 Feb; 56(2):347-52. PubMed ID: 24738942
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
[No Abstract] [Full Text] [Related]
6. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
[No Abstract] [Full Text] [Related]
7. Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
Bolen CR; Mattiello F; Herold M; Hiddemann W; Huet S; Klapper W; Marcus R; Mir F; Salles G; Weigert O; Nielsen T; Oestergaard MZ; Venstrom JM
Blood; 2021 May; 137(19):2704-2707. PubMed ID: 33512481
[No Abstract] [Full Text] [Related]
8. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
[No Abstract] [Full Text] [Related]
9. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
11. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
Bermúdez A; Marco F; Conde E; Mazo E; Recio M; Zubizarreta A
Haematologica; 2000 Aug; 85(8):894-5. PubMed ID: 10942955
[No Abstract] [Full Text] [Related]
12. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
13. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
[No Abstract] [Full Text] [Related]
14. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
[TBL] [Abstract][Full Text] [Related]
16. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Hiraga J; Tomita A; Suzuki N; Takagi Y; Narita M; Kagami Y
Ann Hematol; 2018 Nov; 97(11):2253-2255. PubMed ID: 29725760
[No Abstract] [Full Text] [Related]
17. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.
Yokoyama H; Watanabe T; Maruyama D; Kim SW; Kobayashi Y; Tobinai K
Int J Hematol; 2008 Nov; 88(4):443-447. PubMed ID: 18855101
[TBL] [Abstract][Full Text] [Related]
18. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
Evens AM; Hong F; Habermann TM; Advani RH; Gascoyne RD; Witzig TE; Quon A; Ranheim EA; Ansell SM; Cheema PS; Dy PA; O'Brien TE; Winter JN; Cescon TP; Chang JE; Kahl BS
Clin Cancer Res; 2020 Sep; 26(17):4468-4477. PubMed ID: 32532790
[TBL] [Abstract][Full Text] [Related]
19. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.
Yutaka T; Ito S; Ohigashi H; Naohiro M; Shimono J; Souichi S; Teshima T
Leuk Lymphoma; 2015; 56(11):3216-8. PubMed ID: 25760636
[No Abstract] [Full Text] [Related]
20. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
López-Díaz de Cerio A; García-Muñoz R; Pena E; Panizo Á; Feliu J; Giraldo P; Rodríguez-Calvillo M; Martínez-Calle N; Grande C; Olave MT; Andrade-Campos M; Bandrés E; Núñez-Córdoba JM; Inogés S; Panizo C
Br J Haematol; 2020 Jun; 189(6):1064-1073. PubMed ID: 32130737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
